271980 — Jeil Pharmaceutical Co Income Statement
0.000.00%
Last trade - 00:00
- KR₩254bn
- KR₩301bn
- KR₩726bn
- 47
- 34
- 34
- 28
R2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 671,407 | 691,325 | 700,693 | 722,230 | 726,394 |
Cost of Revenue | |||||
Gross Profit | 151,783 | 156,691 | 155,976 | 156,798 | 184,256 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 670,847 | 677,789 | 709,070 | 735,734 | 717,662 |
Operating Profit | 560 | 13,536 | -8,377 | -13,504 | 8,731 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -554 | 12,552 | -13,834 | -13,247 | 1,916 |
Provision for Income Taxes | |||||
Net Income After Taxes | -10,239 | 6,965 | -14,986 | -15,009 | 5,201 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -10,239 | 6,916 | -12,473 | -13,091 | 5,005 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -10,239 | 6,916 | -12,473 | -13,091 | 5,005 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -712 | 449 | -951 | -899 | 343 |
Dividends per Share |